Sector: Health Care
Director information for COLLEGIUM PHARMACEUTICAL INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Carlos Paya, M.D., Ph.D. | Director; Chair | 67 | ["Venture Partner at Abingworth LLP","Chairman of the board of directors of Vaxcyte, Inc.","Senior Advisor to Ysios Capital","Previous Chairman of Standard BioTools, Inc.","Former President and Chief Executive Officer of Immune Design Corp","Former President of Elan Corporation","Former Vice President of the Lilly Research Laboratories at Eli Lilly & Company","Professor of Medicine, Immunology, and Pathology at the Mayo Clinic"] | ["Transaction","Nominating & Corporate Governance","Transaction Committee"] | 2026 |
| David Dieter | Executive Vice President, General Counsel and Corporate Secretary | 62 | ["B.A. in Economics from the University of Tennessee, Knoxville","J.D. from the University of Illinois College of Law, Champaign","Previous Executive Vice President, General Counsel at Collegium","Independent legal advisor in the biopharma industry","Vice President, Legal at Horizon Therapeutics USA, Inc.","Associate General Counsel at Horizon USA","Vice President, Government Affairs at Takeda","Partner at Freeborn & Peters","Associate at Perkins Coie"] | [] | 2026 |
| Garen Bohlin | Director | 78 | ["Almost 30 years of experience in executive roles at biotechnology companies","Executive Vice President at Constellation Pharmaceuticals, Inc.","Chief Operating Officer at Sirtris Pharmaceuticals, Inc.","President and Chief Executive Officer of Syntonix Pharmaceuticals, Inc.","14 years in executive management at Genetics Institute, Inc.","Partner at Arthur Andersen & Co.","Board member of various companies including Karyopharm Therapeutics, Inc. and Curadel Surgical Innovations, Inc."] | ["Audit (Chair)","Compliance"] | 2026 |
| Gino Santini | Chairman of the Board; Committee Member | 69 | ["Senior advisor providing financing and business consulting services to venture capital, pharmaceutical and biotechnology companies","Senior Vice President of Corporate Strategy and Business Development at Eli Lilly and Company","Member of Lilly’s Executive Committee","President of U.S. Operations at Eli Lilly and Company","Chairman of the board of directors of Compass Pathways PLC","Experience on the board of directors of several other companies"] | ["Compensation","Transaction","Transaction Committee"] | 2026 |
| John Fallon, M.D. | 78 | [] | [] | 2026 | |
| JOHN FREUND, M.D. | Director | 72 | ["Co-founded Skyline Ventures","Served as Managing Director at Skyline until 2023","Co-founded Intuitive Surgical, Inc.","Various positions at Acuson Corporation, most recently as Executive Vice President","General Partner of Morgan Stanley Venture Partners","Co-founded the Healthcare Group in Corporate Finance Department at Morgan Stanley & Co.","Co-founded and was CEO of Arixa Pharmaceuticals"] | ["Compensation","Audit"] | 2026 |
| Michael Donovan | Audit Partner | 60 | ["36 years of experience serving public and private companies in the life sciences industry","Financial expertise","Audit Partner at Ernst & Young LLP since 2002","Office Managing Partner of EY’s biotechnology office in Kendall Square","East Region Biotechnology Leader","B.S. in Business Administration from Merrimack College","Certified Public Accountant (active)"] | [] | 2026 |
| NANCY LURKER | Director | 68 | ["President and Chief Executive Officer of EyePoint Pharmaceuticals, Inc. from November 2016 to July 2023","President and Chief Executive Officer and a director of PDI, Inc.","Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals Corporation","held various senior positions at leading pharmaceutical companies including Pharmacia Corporation, ImpactRx, and Bristol-Myers Squibb Company","Vice Chair of the board of directors of EyePoint","board of directors of Alkermes plc","served on boards of directors of Cancer Treatment Centers of America, Aquestive Therapeutics, Inc., X4 Pharmaceuticals, Inc., Auxilium Pharmaceuticals, Inc., Mallinckrodt plc, Elan Corporation, plc, and ConjuChem Biotechnologies","B.S. in Biology from Seattle Pacific University","M.B.A. from the University of Evansville"] | ["Compliance (Chair)","Compensation"] | 2026 |
| Rita Balice-Gordon, Ph.D. | Chief Executive Officer; Committee Member | 65 | ["Chief Executive Officer of Muna Therapeutics","Founding Chief Scientific Officer of Muna","Entrepreneur-in-residence at Novo Holdings / Novo Seeds","Senior leadership roles at Sanofi, Inc.","Global Head of Rare and Neurological Diseases at Sanofi","Vice President in the Neuroscience and Pain Research Unit at Pfizer, Inc.","Professor of Neuroscience and Chair of the Neuroscience Graduate Group at the University of Pennsylvania Perelman School of Medicine","Adjunct Professor in the Department of Neuroscience"] | ["Nominating and Corporate Governance","Transaction","Transaction Committee"] | 2026 |
| Vikram Karnani | President and Chief Executive Officer | 51 | ["Extensive experience as a senior executive in the pharmaceutical and biotechnology industry","Served as Executive Vice President and President, Global Commercial Operations and Medical Affairs at Amgen","Various leadership positions at Horizon Therapeutics","Held positions at Fresenius Kabi AG and Fenwal Inc.","Master’s degree from Kellogg School of Management at Northwestern University","Master’s degree in electrical engineering from Case Western Reserve University","Bachelor of science degree in electrical engineering from University of Bombay, India"] | [] | 2026 |
